Central Valley(CVCY) - 2025 Q1 - Quarterly Report
2025-05-09 08:30
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 000-31977 COMMUNITY WEST BANCSHARES (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organ ...
Catalyst Biosciences, Inc.(CBIO) - 2025 Q1 - Quarterly Results
2025-05-09 08:30
Exhibit 99.1 Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update Net Income of $3.7 million; reaffirms Full-Year Revenue Guidance of $118–$128 million SAN DIEGO, May 9, 2025 (GLOBE NEWSWIRE) – Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 and provided a business update. 1 • Q1 2025 revenue of $22.1 million; GAAP bas ...
Gyre Therapeutics(GYRE) - 2025 Q1 - Quarterly Results
2025-05-09 08:30
SAN DIEGO, May 9, 2025 (GLOBE NEWSWIRE) – Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced financial results for the first quarter ended March 31, 2025 and provided a business update. "This quarter marked a meaningful step forward in expanding our market presence, particularly in the liver space," said Han Ying, Ph.D., CEO of Gyre Therapeutics. "The successful launch of avatrombopag and our growing commercial footprin ...
Faraday Future(FFIE) - 2025 Q1 - Quarterly Report
2025-05-09 08:16
Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File Number: 001-39395 Faraday Future Intelligent Electric Inc. (Exact name of registrant as specified ...
Fox(FOXF) - 2025 Q1 - Quarterly Report
2025-05-09 07:41
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 4, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-36040 Fox Factory Holding Corp. (Exact name of registrant as specified in its charter) Delaware 26 ...
Natera(NTRA) - 2025 Q1 - Quarterly Report
2025-05-09 07:35
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37478 (Registrant's Telephone Number, Including Area Code) NATERA, INC. (Exact Name of Registrant as Specifie ...
RingCentral(RNG) - 2025 Q1 - Quarterly Report
2025-05-09 07:32
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36089 _____ ...
Inseego (INSG) - 2025 Q1 - Quarterly Report
2025-05-09 07:32
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Exact name of registrant as specified in its charter) 9710 Scranton Road, Suite 200 San Diego, California 92121 (Address of Principal Executive Offices) (Zip Code) (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...
Brookfield Asset Management .(BAM) - 2025 Q1 - Quarterly Report
2025-05-09 07:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission file number: 001-41563 BROOKFIELD ASSET MANAGEMENT LTD. (Exact name of registrant as specified in its charter) British Columbia, Canada 98-170 ...
U.S. Global Investors(GROW) - 2025 Q3 - Quarterly Results
2025-05-09 07:05
Contact: Holly Schoenfeldt Director of Marketing 210.308.1268 hschoenfeldt@usfunds.com Exhibit 99.1 For Immediate Release U.S. Global Investors Reports Results for the Third Quarter of 2025 Fiscal Year, Initiates Strategy to Increase Its Investment in the Bitcoin Ecosystem ********************************************************************************************* SAN ANTONIO–May 8, 2025– U.S. Global Investors, Inc. (NASDAQ: GROW) (the "Company"), a registered investment advisory firm1 with longstanding ex ...